Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement

AIEOPt(8;21); AML; AML1-ETORUNX1-RUNX1T1; CBFB-MYH11; Inv(16); Molecular MRD; Pediatric; RQ-PCR; Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Monitoring; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Proto-Oncogene Proteins; Survival Analysis; Transcription Factors; Translocation, Genetic; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Hematology